DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
Key Details
- 1FDA cleared DeepHealth's Prostate Suite, an AI platform for prostate MRI workflows.
- 2Tool provides AI assistance for lesion detection, risk assessment, segmentation, and PI-RADS reporting.
- 3Compatible with 11 fusion biopsy systems, integrating with radiologists' existing tools.
- 4Real-world use: detected 27% more lesions, reduced segmentation variability by 65%, and cut biopsy workflow times by 37%.
- 5RadNet also received CE Mark in Europe for Brain Health, Brain Age, and LumbarMR AI solutions.
- 6LumbarMR AI supports lumbar spine MRI analysis, added through Gleamer acquisition.
Why It Matters
FDA clearance signals increasing acceptance and integration of AI tools in radiology. These solutions may meaningfully improve cancer detection accuracy, workflow efficiency, and broader access to prostate and other disease screenings.
Source
Radiology Business
Related News
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.